Markus Germann

Markus Germann

Auto-generated profile, based on publicly available information

Markus Germann

Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MGMarkus Germann
Markus Germann
NZNadine Zangger
Nadine Zangger
MSMarc‐Olivier Sauvain
Marc‐Olivier Sauvain
CSChristine Sempoux
Christine Sempoux
ABAmber D Bowler
Amber D Bowler
FRFreddy Radtke
Freddy Radtke
High T‐cell infiltration in colorectal cancer (CRC) correlates with a favorable disease outcome and immunotherapy response. This, however, is only observed in a small subset of CRC patients. A better understanding of the factors influencing tumor T‐cell responses in CRC could inspire novel therapeutic approaches to achieve broader immunotherapy responsiveness. Here, we investigated T cell‐suppressive properties of different myeloid cell types in an inducible colon tumor mouse model. The most potent inhibitors of T‐cell activity were tumor‐infiltrating neutrophils. Gene expression analysis and combined in vitro and in vivo tests indicated that T‐cell suppression is mediated by neutrophil‐secreted metalloproteinase activation of latent TGFβ. CRC patient neutrophils similarly suppressed T cells via TGFβ in vitro, and public gene expression datasets suggested that T‐cell activity is lowest in CRCs with combined neutrophil infiltration and TGFβ activation. Thus, the interaction of neutrophils with a TGFβ‐rich tumor microenvironment may represent a conserved immunosuppressive mechanism in CRC.

21 March 2012 in Stem Cells
Verified
Journal Article
Open access
PDF file
MGMarkus Germann
Markus Germann
AWAntoinette Wetterwald
Antoinette Wetterwald
NGNatalia Guzmán-Ramirez
Natalia Guzmán-Ramirez
GPGabri van der Pluijm
Gabri van der Pluijm
ZCZoran Culig
Zoran Culig
GTGeorge N. Thalmann
George N. Thalmann
Castration is the standard therapy for advanced prostate cancer (PC). Although this treatment is initially effective, tumors invariably relapse as incurable, castration‐resistant PC (CRPC). Adaptation of androgen‐dependent PC cells to an androgen‐depleted environment or selection of pre‐existing, CRPC cells have been proposed as mechanisms of CRPC development. Stem cell (SC)‐like PC cells have been implicated not only as tumor initiating/maintaining in PC but also as tumor‐reinitiating cells in CRPC. Recently, castration‐resistant cells expressing the NK3 homeobox 1 (Nkx3‐1) (CARNs), the other luminal markers cytokeratin 18 (CK18) and androgen receptor (AR), and possessing SC properties, have been found in castrated mouse prostate and proposed as the cell‐of‐origin of CRPC. However, the human counterpart of CARNs has not been identified yet. Here, we demonstrate that in the human PC xenograft BM18, pre‐existing SC‐like and neuroendocrine (NE) PC cells are selected by castration and survive as totally quiescent. SC‐like BM18 cells, displaying the SC markers aldehyde dehydrogenase 1A1 or NANOG, coexpress the luminal markers NKX3‐1, CK18, and a low level of AR (ARlow) but not basal or NE markers. These CR luminal SC‐like cells, but not NE cells, reinitiate BM18 tumor growth after androgen replacement. The ARlow seems to mediate directly both castration survival and tumor reinitiation. This study identifies for the first time in human PC SC‐/CARN‐like cells that may represent the cell‐of‐origin of tumor reinitiation as CRPC. This finding will be fundamental for refining the hierarchy among human PC cancer cells and may have important clinical implications. STEM CELLS2012;30:1076–1086

30 July 2009 in The Prostate
Verified
Journal Article
Closed access
PDF file
NGNatalia Guzmán‐Ramírez
Natalia Guzmán‐Ramírez
MVMaureen Völler
Maureen Völler
AWAntoinette Wetterwald
Antoinette Wetterwald
MGMarkus Germann
Markus Germann
NCNeil Cross
Neil Cross
MCMarco G. Cecchini
Marco G. Cecchini

1 October 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CMClémentine Le Magnen
Clémentine Le Magnen
LBLukas Bubendorf
Lukas Bubendorf
CRCyrill A. Rentsch
Cyrill A. Rentsch
CMChantal Mengus
Chantal Mengus
JGJoel Gsponer
Joel Gsponer
GSGiulio C. Spagnoli
Giulio C. Spagnoli
Purpose: High aldehyde dehydrogenase (ALDH) has been suggested to selectively mark cells with high tumorigenic potential in established prostate cancer cell lines. However, the existence of cells with high ALDH activity (ALDHbright) in primary prostate cancer specimens has not been shown so far. We investigated the presence, phenotype, and clinical significance of ALDHbright populations in clinical prostate cancer specimens. Experimental Design: We used ALDEFLUOR technology and fluorescence-activated cell-sorting (FACS) staining to identify and characterize ALDHbright populations in cells freshly isolated from clinical prostate cancer specimens. Expression of genes encoding ALDH-specific isoforms was evaluated by quantitative real-time PCR in normal prostate, benign prostatic hyperplasia (BPH), and prostate cancer tissues. ALDH1A1-specific expression and prognostic significance were assessed by staining two tissue microarrays that included more than 500 samples of BPH, prostatic intraepithelial neoplasia (PIN), and multistage prostate cancer. Results: ALDHbright cells were detectable in freshly excised prostate cancer specimens (n = 39) and were mainly included within the EpCAM(+) and Trop2(+) cell populations. Although several ALDH isoforms were expressed to high extents in prostate cancer, only ALDH1A1 gene expression significantly correlated with ALDH activity (P < 0.01) and was increased in cancers with high Gleason scores (P = 0.03). Most importantly, ALDH1A1 protein was expressed significantly more frequently and at higher levels in advanced-stage than in low-stage prostate cancer and BPH. Notably, ALDH1A1 positivity was associated with poor survival (P = 0.02) in hormone-naïve patients. Conclusions: Our data indicate that ALDH contributes to the identification of subsets of prostate cancer cells of potentially high clinical relevance. Clin Cancer Res; 19(19); 5361–71. ©2013 AACR.

20 November 2014 in Cell Reports
Verified
Journal Article
Open access
PDF file
HXHuiling Xu
Huiling Xu
YYYuqian Yan
Yuqian Yan
SDSiddhartha Deb
Siddhartha Deb
DRDanny Rangasamy
Danny Rangasamy
MGMarkus Germann
Markus Germann
RRRobert G. Ramsay
Robert G. Ramsay
Rad21 is identified as a critical mediator of ApcWT LOH LOH and CIN are formally documented in vitro in primary intestinal cells Rad21 regulates key CRC-associated genes Rad21 is identified as a key driver of L1 retrotransposon expression

21 March 2015 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
SCSandra Carpinteri
Sandra Carpinteri
SSShienny Sampurno
Shienny Sampurno
MBMaria-Pia Bernardi
Maria-Pia Bernardi
MGMarkus Germann
Markus Germann
JMJordane Malaterre
Jordane Malaterre
RRRobert G. Ramsay
Robert G. Ramsay
Background Conventional laparoscopic surgery uses CO2that is dry and cold, which can damage peritoneal surfaces. It is speculated that disseminated cancer cells may adhere to such damaged peritoneum...